```html

Zollinger‑Ellison Syndrome (Gastrinoma with Hepatic Metastasis)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare neuroendocrine disorder in which one or more gastrin‑producing tumors (gastrinomas) develop, most often in the pancreas or duodenum. These tumors secrete excessive amounts of gastrin, a hormone that stimulates the stomach to produce large volumes of acidic gastric juice. The resulting hyperacidity leads to severe peptic ulcer disease, diarrhea, and malabsorption. When gastrinomas spread to the liver, they are referred to as gastrinoma with hepatic metastasis.

Who it affects: ZES can occur at any age but most patients are diagnosed between 30 and 60 years. Men and women are affected equally. About 25 % of cases are part of the hereditary condition MEN‑1 syndrome (Multiple Endocrine Neoplasia type 1). Sporadic cases account for the remaining 75 %.

Prevalence: Gastrinomas are rare, with an estimated incidence of 0.5–2 cases per million people per year. Hepatic metastasis occurs in roughly 40‑60 % of patients with gastrinomas, making ZES with liver involvement an especially serious form of the disease [NIH, 2023; WHO Neuroendocrine Tumor Fact Sheet, 2022].

Symptoms

Symptoms stem from two main mechanisms: excess gastric acid and tumor burden (especially when the liver is involved).

Gastro‑intestinal symptoms

• Recurrent peptic ulcers – often multiple, large, and located beyond the duodenum (e.g., jejunum).
• Abdominal pain – burning or gnawing pain that may improve with food (duodenal ulcer) or worsen after meals (gastric ulcer).
• Diarrhea – watery, sometimes fatty (steatorrhea) due to acid inactivation of pancreatic enzymes.
• Nausea / vomiting – may be related to ulcer complications or intestinal obstruction.
• Upper gastrointestinal bleeding – melena or hematemesis from ulcer erosion.

Systemic symptoms

• Weight loss – from malabsorption and chronic diarrhea.
• Fatigue – secondary to anemia, electrolyte loss, or cancer‑related cachexia.
• Glossitis & mouth ulcers – acid damage to oral mucosa.

Symptoms related to hepatic metastasis

• Right‑upper‑quadrant abdominal fullness or pain – due to liver enlargement.
• Jaundice – yellowing of skin/eyes if bile ducts are compressed.
• Ascites – fluid accumulation from advanced liver disease.
• Liver function test abnormalities – elevated alkaline phosphatase, bilirubin, or transaminases.

Causes and Risk Factors

Primary causes

• Gastrin‑producing neuroendocrine tumors – usually arising in the duodenum (≈70 %) or pancreas (≈25 %).
• Genetic mutation in MEN‑1 gene – autosomal dominant; leads to multiple endocrine tumors, including gastrinomas.

Risk factors

• Family history of MEN‑1 or other endocrine neoplasias.
• Known genetic mutations (e.g., MEN1 or CDKN1B).
• Prior diagnosis of other neuroendocrine tumors.
• Chronic use of proton‑pump inhibitors (PPIs) does not cause ZES, but may mask symptoms, delaying diagnosis.

Although most cases are sporadic with no identifiable trigger, recognizing a familial pattern should prompt genetic counseling and earlier screening. [Cleveland Clinic, 2023; NIH Genetics Home Reference, 2022].

Diagnosis

Because ZES can mimic common ulcer disease, a high index of suspicion is required, especially in patients with refractory ulcers or ulcers distal to the duodenum.

Laboratory tests

• Fasting serum gastrin level – markedly elevated (>1000 pg/mL) in classic ZES; values >10× upper limit of normal with gastric pH < 2 are diagnostic.
• Secretin stimulation test – paradoxical rise in gastrin after IV secretin (≥ 120 pg/mL increase).
• Basic metabolic panel – to assess potassium, magnesium, and bicarbonate (often low due to diarrhea).
• Liver function tests – especially if hepatic metastasis is suspected.

Imaging studies

• Endoscopic ultrasound (EUS) – high‑resolution detection of small pancreatic or duodenal lesions.
• Multiphasic contrast‑enhanced CT or MRI – evaluates primary tumor size, local invasion, and liver metastases.
• Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT – highly sensitive for neuroendocrine tumor localization and staging.
• Selective arterial secretin stimulation test – used when imaging fails to pinpoint the lesion.

Pathology

If a lesion is surgically removed or biopsied, histology confirms a well‑differentiated neuroendocrine tumor, usually graded by Ki‑67 proliferative index (G1‑G3). Immunohistochemistry is positive for gastrin and somatostatin receptors.

Treatment Options

Treatment aims to control acid hypersecretion, remove or reduce tumor burden, and manage liver metastases.

Acid‑blocking therapy (first‑line)

• High‑dose proton‑pump inhibitors (PPIs) – omeprazole 60 mg daily or equivalent; may need up‑titration to 120 mg.
• Histamine‑2 receptor antagonists (H2RAs) – used adjunctively or when PPIs are not tolerated.

Effective acid control reduces ulcer complications and improves quality of life. [Mayo Clinic, 2024].

Surgical management

• Curative resection – enucleation or pancreaticoduodenectomy for localized gastrinomas without metastasis.
• Liver‑directed therapies – hepatic resection, radiofrequency ablation (RFA), or transarterial embolization (TAE) for limited metastases.
• Debulking surgery – removal of > 90 % of tumor burden can improve symptom control even when cure isn’t possible.

Medical therapy for unresectable or metastatic disease

• Somatostatin analogues (SSA) – octreotide or lanreotide; inhibit gastrin release and have anti‑tumor effects.
• Targeted therapy – everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) for progressive neuroendocrine tumors.
• Peptide‑Receptor Radionuclide Therapy (PRRT) – ^177Lu‑DOTATATE; delivers radiation directly to somatostatin‑receptor‑positive cells.
• Chemotherapy – reserved for high‑grade (G3) or rapidly progressing disease; regimens often include streptozocin, 5‑fluorouracil, or capecitabine/temozolomide.

Liver‑specific options

• Radioembolization (Y‑90) for extensive hepatic disease.
• Liver transplantation – highly selective, considered only in carefully screened patients with liver‑only disease and no extra‑hepatic spread.

Lifestyle & supportive care

• Small, frequent meals; avoid irritants (spicy foods, alcohol, caffeine).
• Maintain hydration and replace electrolytes lost to diarrhea.
• Bone health monitoring – chronic PPI use may affect calcium absorption; supplement vitamin D & calcium as needed.

Living with Zollinger‑Ellison Syndrome (gastrinoma with hepatic metastasis)

Daily management tips

• Medication adherence – take PPIs exactly as prescribed; missing doses can precipitate ulcer bleeding.
• Monitor stool consistency – keep a diary; sudden increase in watery stools may signal disease progression.
• Regular follow‑up imaging – typically every 3–6 months for metastatic disease.
• Nutrition – work with a dietitian experienced in high‑acid conditions; a low‑fat, low‑fiber diet may reduce diarrhea.
• Vaccinations – hepatitis A/B, influenza, and COVID‑19 vaccines are especially important for patients with liver involvement.
• Psychosocial support – connect with patient groups (e.g., Neuroendocrine Tumor Research Foundation) to share experiences and coping strategies.

What to track and report to your provider

• New or worsening abdominal pain.
• Signs of gastrointestinal bleeding (black stools, vomiting blood).
• Sudden weight loss > 5 % body weight.
• Changes in liver‑related labs (bilirubin, alkaline phosphatase).
• Side effects from medications (e.g., severe constipation from high‑dose PPIs).

Prevention

Because ZES is largely driven by tumor biology, primary prevention is limited. However, you can reduce the impact of disease and lower the risk of complications:

• Early detection in families with MEN‑1 – genetic counseling and periodic gastrin level testing.
• Prompt evaluation of refractory or atypical ulcers; do not self‑treat with OTC antacids alone.
• Avoid chronic NSAID or aspirin use unless directed by a physician, as these can exacerbate ulcer disease.
• Maintain a healthy weight and limit alcohol, which can worsen liver injury.

While you cannot prevent the tumor itself, vigilant surveillance and lifestyle choices can improve outcomes [CDC Cancer Prevention, 2024].

Complications

If left untreated or poorly controlled, ZES can lead to serious health problems:

• Perforated peptic ulcer – surgical emergency with risk of peritonitis.
• Upper gastrointestinal bleeding – may require endoscopic hemostasis or surgery.
• Severe malabsorption – leading to anemia, osteoporosis, and vitamin deficiencies.
• Liver failure – from progressive metastatic disease or treatment‑related toxicity.
• Pancreatitis – occasional complication of pancreatic gastrinomas.
• Neuroendocrine tumor progression – higher‑grade disease with shorter survival.

Overall 5‑year survival for patients with localized gastrinoma exceeds 80 %, but drops to 40‑55 % when liver metastases are present [WHO Neuroendocrine Tumors Survival Data, 2023].

When to Seek Emergency Care

For non‑emergent concerns, contact your gastroenterology or oncology team during regular office hours.

---

Sources: Mayo Clinic. “Zollinger‑Ellison syndrome.” 2024; CDC. “Neuroendocrine Tumors.” 2024; NIH National Cancer Institute. “Gastrinoma.” 2023; WHO. “Neuroendocrine Tumor Fact Sheet.” 2022; Cleveland Clinic. “MEN‑1 and Gastrinomas.” 2023; Peer‑reviewed journals: JAMA Oncology 2022; Annals of Surgery 2021.

``` *Word count: approximately 1,340 words.*